New pill shows promise for rare blood disorder in phase 3 trial
NCT ID NCT06799546
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new pill called HSK39297 against a standard infusion drug (eculizumab) in 73 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. Participants had not received prior complement inhibitor treatment. The main goal was to see if the pill could raise hemoglobin levels without needing blood transfusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNH are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, 210029, China
-
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for PNH patients: Long-Term drug safety confirmed
- New study tracks safety of danicopan Add-On for rare blood disorder
- New drug combo for rare blood disease under safety watch
- New hope for PNH patients: early access to danicopan combo therapy
- New hope for rare blood disorder: ravulizumab trial shows promise in china
- New drug combo aims to boost red blood cells in kids with rare blood disorder